Related Experiment Video
Updated: Apr 15, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Emerging formats for next-generation antibody drug conjugates
Mahendra P Deonarain1, Gokhan Yahioglu, Ioanna Stamati
1Antikor Biopharma Ltd, Stevenage Bioscience Catalyst , Gunnels Wood Road, Stevenage, Herts, SG1 2FX , UK.
Antibody-drug conjugates (ADCs) are advancing in oncology pipelines. Innovations in antibody formats and conjugation strategies are improving efficacy and therapeutic index for better cancer treatment.
Area of Science:
- Biotechnology
- Oncology
- Pharmaceutical Sciences
Background:
- Antibody-drug conjugates (ADCs) represent a significant portion of biopharma's oncology pipeline.
- Advances in understanding and optimizing ADC components drive innovation.
Purpose of the Study:
- To review emerging antibody formats and their impact on ADC design and performance.
- To discuss innovations in protein engineering and conjugation strategies for ADCs.
Main Methods:
- Review of published research, patent applications, and conference disclosures.
- Analysis of various antibody formats, conjugation chemistries, and their effects.
Main Results:
- Emergence of diverse antibody formats beyond whole immunoglobulins.
- New chemistries offer improved stability, drug:antibody ratio, pharmacokinetics, and efficacy.
- Different antibody sizes aim to enhance tumor penetration and reduce side effects.
Conclusions:
- ADCs are entering a new evolutionary phase with novel formats.
- Clinical evaluation will determine the benefits of these advanced ADC formats.
- Smaller or fragment-based ADCs are expected to broaden oncological applications.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
06:48Antibody Labeling with Fluorescent Dyes Using Magnetic Protein A and Protein G Beads
Published on: September 15, 2016
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Modified-Release Drug Delivery Systems: Site-Targeted